RESUMEN
Recent studies have demonstrated that CXCL13 serum levels correlate significantly with systemic lupus erythematosus (SLE) disease activity. However, experimental studies show that CXCL13 production can also be induced by bacterial exposure as well as in response to inflammatory cytokines. This report asks whether CXCL13 serum levels are elevated in patients with evidence of bacterial infections and whether there is a correlation with the C-reactive protein (CRP) levels or the severity of illness in critically ill patients. CXCL13 levels were compared in 39 patients with active SLE (without concomitant infection), 40 non-SLE patients with sepsis, and 40 healthy controls by enzyme-linked immunosorbent assay (ELISA) methodology. We also tested storage conditions and freeze-thaw cycles for stability of CXCL13 in serum samples. Our studies demonstrated that the median CXCL13 serum levels were significantly elevated in patients with SLE [median 83 pg/ml (interquartile range 38-366)] or sepsis [359 pg/ml (151-459)] compared with healthy controls [32 pg/ml (27-41), p < 0.001]. The CXCL13 serum levels correlated with disease activity in SLE (CXCL13 vs. SLEDAI r = 0.65, p < 0.001), but were not associated with severity of illness score in critically ill patients (CXCL13 vs. SOFA r = -0.15, p = 0.35). However, CXCL13 serum levels were clearly associated with CRP levels in both sepsis (r = 0.45, p = 0.003) and SLE (r = 0.39, p = 0.02). In conclusion, CXCL13 is a stable serum marker for disease activity in SLE patients, but concomitant infections can also lead to increased CXCL13 levels.
Asunto(s)
Quimiocina CXCL13/sangre , Lupus Eritematoso Sistémico/sangre , Sepsis/sangre , Adulto , Anciano , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estabilidad Proteica , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Only a few gastrointestinal diseases develop specifically at advanced ages (e.g. Zenker diverticulum, atrophic gastritis, mesenterial ischaemia). However, the frequency of certain diseases increases and various illnesses are found to take other, mostly silent, courses in elderly people. As a rule, more complications in gastrointestinal diseases are to be expected and the presence of comorbidities can make diagnosis and therapy more difficult. The possibility of tumours should always be considered in the differential diagnosis of elderly patients. The diagnosis and treatment of elderly patients for gastrointestinal diseases are no different from that of other age groups.
Asunto(s)
Enfermedades Gastrointestinales/diagnóstico , Neoplasias Gastrointestinales/diagnóstico , Isquemia/diagnóstico , Factores de Edad , Anciano , Comorbilidad , Estudios Transversales , Diagnóstico Diferencial , Gastritis Atrófica/complicaciones , Gastritis Atrófica/diagnóstico , Gastritis Atrófica/epidemiología , Enfermedades Gastrointestinales/complicaciones , Enfermedades Gastrointestinales/epidemiología , Neoplasias Gastrointestinales/complicaciones , Neoplasias Gastrointestinales/epidemiología , Humanos , Intestinos/irrigación sanguínea , Isquemia/complicaciones , Isquemia/epidemiología , Oclusión Vascular Mesentérica/complicaciones , Oclusión Vascular Mesentérica/diagnóstico , Oclusión Vascular Mesentérica/epidemiología , Divertículo de Zenker/complicaciones , Divertículo de Zenker/diagnóstico , Divertículo de Zenker/epidemiologíaRESUMEN
In this study nine colorectal cancer cell lines were analysed by 10K SNP-arrays and spectral karyotyping (SKY). Complex chromosomal alterations and breakpoints of deleted or translocated fragments found by SKY could further be characterized by SNP-array analysis. Interestingly many monoallelic regions identified by SNP-array analysis display no copy number alterations, representing uniparental disomy (UPD). It was demonstrated that UPD seems to be involved in activation of early-acting tumor suppressor genes in MSS- (APC, CDKN2A) and MSI- (MLH1, MSH2, APC, CDKN2A) colorectal cancer cell lines. Genes involved later on in the adenoma-carcinoma sequence (i.e. TP53/SMAD4) were not found to be inactivated by UPD. Furthermore, identified amplified monoallelic regions may include oncogenes activated by allele-specific-amplification (i.e. Cyclin D1). However, at present, the majority of the monoallelic regions located in the present study have not yet been associated with known tumor suppressor genes and oncogenes. Further studies are warranted to identify relevant genes in the respective regions and to further verify the results presented here.
Asunto(s)
Neoplasias Colorrectales/genética , Mutación , Polimorfismo de Nucleótido Simple , Disomía Uniparental , Alelos , Línea Celular Tumoral , Neoplasias Colorrectales/patología , Genotipo , Humanos , CariotipificaciónRESUMEN
Second only to cardiovascular diseases, malignant tumors are the most common fatal disease, with malignant neoplasms in the gastrointestinal tract playing an important role. Underlying the most numerous of these malignancies is a complex interaction between genetic and environmental factors. The data relating to the role of environmental factors (for the most part dietary factors) in the development of gastrointestinal tumors derive mainly from, epidemiological research. The current evidence is "convincin" with regard to complex lifestyle patterns, but at most "plausible" when the chemically defined individual substances are considered. Summarizing the potential protective value of dietary factors reveals that the risk of contracting the majority of the gastrointestinal tumors can be reduced by increasing the intake of fruit and vegetables. An additional protective effect is associated with a balanced diet, physical activity, preservation of normal weight, avoidance of smoking, and moderation in the amount of alcohol consumed.
Asunto(s)
Conducta Alimentaria , Frutas , Neoplasias Gastrointestinales/prevención & control , Verduras , Comparación Transcultural , Estudios Transversales , Neoplasias Gastrointestinales/epidemiología , Neoplasias Gastrointestinales/etiología , Conductas Relacionadas con la Salud , Humanos , Estilo de Vida , Factores de RiesgoRESUMEN
Due to its low digestibility in the small intestine, a major fraction of the polyol isomalt reaches the colon. However, little is known about effects on the intestinal microflora. During two 4-week periods in a double-blind, placebo-controlled, cross-over design, nineteen healthy volunteers consumed a controlled basal diet enriched with either 30 g isomalt or 30 g sucrose daily. Stools were collected at the end of each test phase and various microbiological and luminal markers were analysed. Fermentation characteristics of isomalt were also investigated in vitro. Microbiological analyses of faecal samples indicated a shift of the gut flora towards an increase of bifidobacteria following consumption of the isomalt diet compared with the sucrose diet (P<0.05). During the isomalt phase, the activity of bacterial beta-glucosidase decreased (P<0.05) whereas beta-glucuronidase, sulfatase, nitroreductase and urease remained unchanged. Faecal polyamines were not different between test periods with the exception of cadaverine, which showed a trend towards a lower concentration following isomalt (P=0.055). Faecal SCFA, lactate, bile acids, neutral sterols, N, NH3, phenol and p-cresol were not affected by isomalt consumption. In vitro, isomalt was metabolized in several bifidobacteria strains and yielded high butyrate concentrations. Isomalt, which is used widely as a low-glycaemic and low-energy sweetener, has to be considered a prebiotic carbohydrate that might contribute to a healthy luminal environment of the colonic mucosa.
Asunto(s)
Colon/metabolismo , Carbohidratos de la Dieta/administración & dosificación , Disacáridos/administración & dosificación , Heces/microbiología , Alcoholes del Azúcar/administración & dosificación , Edulcorantes/administración & dosificación , Adulto , Amoníaco/análisis , Bifidobacterium/aislamiento & purificación , Ácidos y Sales Biliares/análisis , Recuento de Colonia Microbiana/métodos , Cresoles/análisis , Grasas/análisis , Ácidos Grasos Volátiles/análisis , Heces/química , Femenino , Fermentación/fisiología , Humanos , Concentración de Iones de Hidrógeno , Hibridación Fluorescente in Situ/métodos , Lactatos/análisis , Masculino , Persona de Mediana Edad , Nitrógeno/análisis , Fenol/análisis , Poliaminas/análisis , Esteroles/análisisRESUMEN
The polyol isomalt (Palatinit) is a well established sugar replacer. The impact of regular isomalt consumption on metabolism and parameters of gut function in nineteen healthy volunteers was examined in a randomised, double-blind, cross-over trial with two 4-week test periods. Volunteers received 30 g isomalt or 30 g sucrose daily as part of a controlled diet. In addition to clinical standard diagnostics, biomarkers and parameters currently discussed as risk factors for CHD, diabetes or obesity were analysed. Urine and stool Ca and phosphate excretions were measured. In addition, mean transit time, defecation frequency, stool consistency and weight were determined. Consumption of test products was affirmed by the urinary excretion of mannitol. Blood lipids were comparable in both phases, especially in volunteers with hyperlipidaemia, apart from lower apo A-1 (P=0.03) for all subjects. Remnant-like particles, oxidised LDL, NEFA, fructosamine and leptin were comparable and not influenced by isomalt. Ca and phosphate homeostasis was not affected. Stool frequency was moderately increased in the isomalt phase (P=0.006) without changes in stool consistency and stool water. This suggests that isomalt is well tolerated and that consumption of isomalt does not impair metabolic function or induce hypercalciuria. In addition, the study data indicate that isomalt could be useful in improving bowel function.
Asunto(s)
Digestión/efectos de los fármacos , Disacáridos/administración & dosificación , Hiperlipidemias/metabolismo , Alcoholes del Azúcar/administración & dosificación , Edulcorantes/administración & dosificación , Adulto , Análisis de Varianza , Calcio/análisis , Calcio/orina , Estudios Cruzados , Defecación , Disacáridos/química , Método Doble Ciego , Heces/química , Femenino , Flatulencia , Motilidad Gastrointestinal/efectos de los fármacos , Tránsito Gastrointestinal/efectos de los fármacos , Humanos , Masculino , Manitol/orina , Persona de Mediana Edad , Fosfatos/análisis , Fosfatos/orina , Sacarosa/administración & dosificación , Alcoholes del Azúcar/química , Edulcorantes/químicaRESUMEN
AIM: The presentation of solid pseudopapillary tumors of the pancreas (SPTP) with examples of our own surgical department. SPTP occur typically in young women or in children and are for most of benign behavior. In about 5 % a malignant course with occurrence of metastases can develop. METHODS: Diagnosis, morphological and histological findings and therapeutic approach are described in three cases. The differential diagnosis of other tumors of the pancreas is discussed. FINDINGS: Three women (age 21, 33 and 43) with SPTP have been treated in the Department of Surgery at the University of Würzburg between 1997-1999. All tumors were resected curatively. No adjuvant treatment was performed. The follow up ranged from 31-56 months. No relapse of disease or occurrence of metastases were observed. All resected specimen revealed the typical character of SPTP with areas of solid parts and hemorrhage within the tumor. A panel of immunohistological markers (Vimentin, N-Cam, NSE, Chromogranin, Synaptophysin, Ck7, Ck19, Ck20, EMA) and expression of receptors were investigated. CONCLUSION: The diagnosis of this rare tumor can be made clinically and intraoperatively according to its typical morphology and occurrence, predominantly in young women or in children thus helping to perform adequate surgical therapy.
Asunto(s)
Páncreas/patología , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patología , Adulto , Niño , Diagnóstico Diferencial , Femenino , Humanos , Inmunohistoquímica , Masculino , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/cirugía , Seudoquiste Pancreático/diagnóstico , Pronóstico , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND AND AIMS: Short chain fatty acids (SCFA) exert profound effects on the colonic mucosa. In particular, SCFA modulate mucosal immune functions. The antimicrobial cathelicidin LL-37 is expressed by colon epithelial cells. In the present study the effect of SCFA on LL-37 expression was investigated. METHODS: LL-37 expression in vivo was assessed by immunohistochemistry. Real time quantitative reverse transcription-polymerase chain reaction was employed to determine LL-37 expression in colonocytes in vitro after treatment with various cytokines, SCFA, or flavone. LL-37 levels were correlated to cell differentiation which was determined by alkaline phosphatase (AP) activity. In addition, intracellular signalling pathways such as MEK-ERK (mitogen/extracellular signal protein kinase (MEK)/extracellular signal regulated protein kinase (ERK)) and p38/mitogen activated protein (MAP) kinase were explored. RESULTS: In vivo, LL-37 expression in healthy mucosa was restricted to differentiated epithelial cells in human colon and ileum. In colonocytes, increased LL-37 expression associated with cell differentiation was detected in vitro following treatment with butyrate, isobutyrate, propionate, and trichostatin A. Flavone induced LL-37 transcription but did not affect AP activity while cytokines had no effect. To dissect pathways mediating differentiation and LL-37 expression, specific inhibitors were applied. Inhibition of the protein kinase MEK enhanced butyrate induced AP activity while LL-37 expression in colon epithelial cells was blocked. In contrast, inhibition of p38/MAP kinase blocked cell differentiation without inhibiting LL-37 expression. CONCLUSIONS: Expression of the cathelicidin LL-37 in colonocytes and cellular differentiation are separately modulated by SCFA via distinct signalling pathways. These data may provide a rationale for dietary modulation of mucosal defence mechanisms.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/metabolismo , Colon/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Ácidos Grasos Volátiles/farmacología , Transducción de Señal/fisiología , Adulto , Fosfatasa Alcalina/metabolismo , Apoptosis/efectos de los fármacos , Biopsia , Butiratos/farmacología , Catelicidinas , Diferenciación Celular/fisiología , Línea Celular , Colon/citología , Células Epiteliales/metabolismo , Flavonas , Flavonoides/farmacología , Humanos , Ácidos Hidroxámicos/farmacología , Inmunohistoquímica/métodos , Mucosa Intestinal/citología , Mucosa Intestinal/efectos de los fármacos , Proteínas Quinasas/metabolismo , Inhibidores de la Síntesis de la Proteína/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodosRESUMEN
The baroreflex mechanism is a central part of the regulation of the cardiovascular system, particularly in the control of vagal and sympathetic outflow to the heart and the peripheral circulation. Failure of the baroreflex is a rare cause of secondary hypertension. It is characterized by drastic changes in sympathetic activation and blood pressure following complete denervation of the baroreflex. Here, we report a case of baroreflex failure following bilateral carotid artery surgery and radiation. Moreover, postoperative orthostatic hypotension with recurrent syncope suggests a rare subform, the selective baroreflex failure, where efferent parasympathetic activity is preserved. Both high blood pressure and orthostatically induced syncope improved substantially after treatment with clonidine.
Asunto(s)
Barorreflejo/fisiología , Estenosis Carotídea/cirugía , Hipertensión/diagnóstico , Hipotensión Ortostática/diagnóstico , Complicaciones Posoperatorias/diagnóstico , Reflejo Anormal/fisiología , Arterias Carótidas/efectos de la radiación , Arterias Carótidas/cirugía , Estenosis Carotídea/radioterapia , Terapia Combinada , Endarterectomía Carotidea , Femenino , Corazón/inervación , Humanos , Hipertensión/fisiopatología , Hipotensión Ortostática/fisiopatología , Enfermedad Iatrogénica , Persona de Mediana Edad , Complicaciones Posoperatorias/fisiopatología , Sistema Nervioso Simpático/fisiopatología , Nervio Vago/fisiopatologíaRESUMEN
Laboratory and epidemiological studies suggest that butyrate, a metabolic product of microbial fermentation of dietary fibre, and aspirin, a non-steroidal antiphlogistic drug, both reduce the risk of developing colon cancer. Notably, few data exist on potential interactions of these two substances. In this study, the effects of a butyrate-aspirin combination on human colon cancer cells were compared with treatment with aspirin or butyrate alone. Both substances decreased proliferation and induced differentiation and apoptosis. Butyrate reduced mutant p53 expression, whereas aspirin did not affect p53 expression. Butyrate-induced apoptosis correlated with an increase in Bak expression and a decrease in the expression of Bcl-XL. Aspirin had no effect on the investigated apoptosis-controlling factors. The antiproliferative and pro-apoptotic effects of the butyrate-aspirin combination were markedly enhanced. The combination resulted in a stronger decrease in the expression of PCNA and cdk2. Our data suggest that the anticarcinogenic effect of aspirin might effectively be augmented by combination with the short-chain fatty acid butyrate.
Asunto(s)
Apoptosis/efectos de los fármacos , Aspirina/administración & dosificación , Butiratos/administración & dosificación , Neoplasias Colorrectales/patología , Técnicas de Cultivo de Célula/métodos , Neoplasias Colorrectales/tratamiento farmacológico , Quimioterapia Combinada , Humanos , Células Tumorales CultivadasRESUMEN
BACKGROUND: In ulcerative colitis (UC) the activation (i.e. nuclear translocation) of nuclear factor kappa B (NF-kappaB) is an important step in the regulation of cytokines secreted by lamina propria macrophages. Clinical trials suggest anti-inflammatory effects of locally administered butyrate in UC. The potential effects of butyrate on NF-kappaB activation in lamina propria macrophages of UC patients were investigated. METHODS: Eleven patients with distal UC were treated for up to 8 weeks with butyrate at 100 mM (n = 6) or placebo (n = 5) enemas. At entry and after 4 and 8 weeks, clinical status was noted and intestinal inflammation was graded endoscopically and histologically. Double-staining with antibodies against NF-kappaB (p65) and CD68 was employed to detect NF-kappaB and macrophages, respectively. RESULTS: In untreated patients, nuclear translocation of NF-kappaB was detectable in virtually all macrophages. Butyrate treatment for 4 and 8 weeks resulted in a significant reduction in the number of macrophages being positive for nuclear translocated NF-kappaB. In addition, butyrate significantly reduced both the number of neutrophils in crypt and surface epithelia and of the lamina propria lymphocytes/plasma cells. These findings correlated with a significant decrease in the Disease Activity Index (DAI). CONCLUSIONS: The decrease in DAI and mucosal inflammation in butyrate-treated patients is associated with a reduction of NF-kappaB translocation in lamina propria macrophages. Since the inflammatory process in UC is mainly sustained by macrophage-derived cytokines, the known anti-inflammatory effects of butyrate may in part be mediated by an inhibition of NF-kappaB activation in these macrophages.
Asunto(s)
Butiratos/uso terapéutico , Colitis Ulcerosa/metabolismo , Mucosa Intestinal/patología , Macrófagos/metabolismo , FN-kappa B/metabolismo , Adulto , Butiratos/administración & dosificación , Colitis Ulcerosa/tratamiento farmacológico , Colitis Ulcerosa/patología , Colon/patología , Enema , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , FN-kappa B/efectos de los fármacosRESUMEN
Lipoxygenase metabolites of arachidonic acid can act as growth promoting factors for various cancer cell lines. Here we demonstrate that the 5-lipoxygenase inhibitor nordihydroguaiaretic acid potently inhibits anchorage-independent growth of human pancreatic and cervical cancer cells in soft agar and delays growth of pancreatic and cervical tumours established in athymic mice. Furthermore, nordihydroguaiaretic acid induces apoptosis of these cancer cells in vitro and in vivo. Potential mechanisms mediating these effects of nordihydroguaiaretic acid were examined. Nordihydroguaiaretic acid had no inhibitory effect on growth and survival signals such as tyrosine phosphorylation of the epidermal growth factor receptor or basal and growth factor-stimulated activities of extracellular signal-regulated kinase 1/2, p70(s6k) and AKT but selectively inhibited expression of cyclin D1 in the cancer cells. In addition, treatment with nordihydroguaiaretic acid lead to a disruption of the filamentous actin cytoskeleton in human pancreatic and cervical cancer cells which was accompanied by the activation of Jun-NH(2)-terminal kinase and p38(mapk). Similar effects were obtained by treatment of the cancer cells with cytochalasin D. These results suggest that nordihydroguaiaretic acid induces anoikis-like apoptosis as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases. In conclusion, nordihydroguaiaretic acid could constitute a lead compound in the development of novel therapeutic agents for various types of cancer.
Asunto(s)
Apoptosis/efectos de los fármacos , División Celular/efectos de los fármacos , Inhibidores de la Lipooxigenasa/farmacología , Masoprocol/farmacología , Neoplasias Pancreáticas/patología , Neoplasias del Cuello Uterino/patología , Actinas , Animales , Western Blotting , Adhesión Celular , Citoesqueleto/patología , Femenino , Humanos , Ratones , Proteínas Quinasas/biosíntesis , Proteínas Quinasas/farmacología , Trasplante Heterólogo , Células Tumorales CultivadasRESUMEN
We have characterized the effects of different short-chain fatty acids (SCFAs) on cell growth and differentiation as well as the phosphorylation state of ERK1 and 2 in the human colon adenocarcinoma cell line HT-29. Of the five SCFAs tested, only butyrate and propionate impaired cellular proliferation. Moreover, butyrate and propionate specifically resulted in a decrease in ERK1 and 2 phosphorylation at 3 and 6 hours post-treatment, suggesting a correlation between the ability of these SCFAs to inhibit cellular proliferation and decrease ERK phosphorylation. Notably, the decrease in ERK phosphorylation was observed prior to the induction of the differentiation markers alkaline phosphatase (AP) and carcinoembryonic antigen (CEA) by butyrate and propionate from days 6 to 18 post-treatment. In the case of butyrate- and propionate-induced differentiation, ERK phosphorylation is a marker and may play a role in the proliferation and/or differentiation states of this cell line.
Asunto(s)
Butiratos/farmacología , Diferenciación Celular , Células HT29/enzimología , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Propionatos/farmacología , Fosfatasa Alcalina/análisis , Fosfatasa Alcalina/metabolismo , Antígeno Carcinoembrionario/análisis , Antígeno Carcinoembrionario/metabolismo , Regulación hacia Abajo , Humanos , Proteína Quinasa 3 Activada por Mitógenos , Fosforilación , Transducción de SeñalRESUMEN
Nuclear factor-kappa B (NF-kappaB) is a critical transcription factor for the inducible expression of multiple genes involved in inflammation. NF-kappaB is sequestered in the cytoplasm by inhibitory IkappaB proteins. Extracellular stimuli, notably interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) activate NF-kappaB nuclear translocation via IkappaB phosphorylation and degradation. Since previous reports suggest that the short chain fatty acid butyrate has antiinflammatory properties, the effects of butyrate on NF-kappaB nuclear translocation in human epithelial cells (HeLa229) were tested. In cells pretreated with butyrate, a time- and dose-dependent inhibition of IL-1beta-mediated NF-kappaB nuclear translocation was observed. However, IkappaB alpha phosphorylation and degradation occurred rapidly in both butyrate pretreated and nonpretreated cells, respectively. These data indicate that inhibition of IL-1beta-induced NF-kappaB activation by butyrate does not require an intact IkappaB alpha protein.
Asunto(s)
Butiratos/farmacología , Interleucina-1/fisiología , FN-kappa B/fisiología , Translocación Genética/efectos de los fármacos , Células HeLa , Humanos , Inmunohistoquímica , FN-kappa B/genética , FosforilaciónRESUMEN
Butyrate, a short-chain fatty acid, is generated by anaerobic fermentation within the colon. Clinical trials suggest that short-chain fatty acids ameliorate inflammation in ulcerative colitis. Nuclear factor (NF) kappaB, an inducible transcription factor that is activated in inflamed colonic tissue, is sequestered to the cytoplasm by its inhibitory IkappaB proteins. The anti-inflammatory effects of butyrate are associated with an inhibition of NF-kappaB nuclear translocation. To investigate the mechanism of NF-kappaB inhibition we examined the effects of butyrate on IkappaBalpha. Human adenocarcinoma cells (SW480, SW620, and HeLa229) were treated with butyrate for up to 48 h followed by tumor necrosis factor (TNF) alpha stimulation. NF-kappaB was detected by immunofluorescence staining with an antibody against its p65 subunit. Levels of IkappBalpha and phosphorylated IkappaBalpha were determined by western blot. Stimulation with TNFalpha resulted in rapid phosphorylation and degradation of IkappaBalpha followed by NF-kappaB nuclear translocation. Butyrate pretreatment successfully inhibited NF-kappaB activation. Pretreatment of adenocarcinoma cells with butyrate is associated with inhibition of TNFalpha-mediated phosphorylation and degradation of IkappaBalpha and effective blocking of NF-kappaB nuclear translocation. The anti-inflammatory effects of butyrate may at least in part be mediated by an inhibition of IkappaBalpha mediated activation of NF-kappaB.
Asunto(s)
Butiratos/farmacología , Proteínas de Unión al ADN/efectos de los fármacos , Proteínas I-kappa B , FN-kappa B/efectos de los fármacos , Factor de Necrosis Tumoral alfa/farmacología , Adenocarcinoma/metabolismo , Western Blotting/métodos , Núcleo Celular/metabolismo , Citocinas/fisiología , Proteínas de Unión al ADN/fisiología , Técnica del Anticuerpo Fluorescente/métodos , Células HeLa/efectos de los fármacos , Humanos , Inhibidor NF-kappaB alfa , FN-kappa B/fisiología , FosforilaciónAsunto(s)
Anticarcinógenos/uso terapéutico , Carcinoma/prevención & control , Neoplasias Colorrectales/prevención & control , Dieta , Prevención Primaria/métodos , Antiinflamatorios no Esteroideos/uso terapéutico , Carcinoma/dietoterapia , Carcinoma/tratamiento farmacológico , Carcinoma/etiología , Neoplasias Colorrectales/dietoterapia , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/etiología , Suplementos Dietéticos , Eflornitina/uso terapéutico , Estrógenos/uso terapéutico , Etanol/efectos adversos , Ejercicio Físico , Alemania , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Factores de Riesgo , Fumar/efectos adversos , Vitaminas/uso terapéuticoRESUMEN
There is convincing evidence that nutrition affects colorectal carcinogenesis in a complex fashion. Dietary components either promote or inhibit the carcinogenic process. The composition of dietary fats seems to be less important as a promoting factor than a positive energy balance, especially in combination with low physical activity. Excessive consumption of red meat is associated with increased risk, which may be due to the heme contained in myoglobin. Alcohol stimulates cell proliferation in the rectum and may thus increase cancer risk. Complex carbohydrates (e.g., dietary fiber) are degraded in the colon to short-chain fatty acids which exhibit protective effects in experimental models of carcinogenesis. The putative protection from vitamins and trace elements merits further attention.
Asunto(s)
Neoplasias Colorrectales/etiología , Fenómenos Fisiológicos de la Nutrición , Animales , Estudios de Casos y Controles , Bovinos , Ensayos Clínicos como Asunto , Estudios de Cohortes , Neoplasias Colorrectales/prevención & control , Carbohidratos de la Dieta/administración & dosificación , Grasas de la Dieta/efectos adversos , Fibras de la Dieta/administración & dosificación , Ingestión de Energía , Etanol/efectos adversos , Humanos , Carne/efectos adversos , Modelos Teóricos , Esfuerzo Físico , Estudios Prospectivos , Factores de Riesgo , Oligoelementos/administración & dosificación , Vitaminas/administración & dosificaciónRESUMEN
The cell lines SW480 and SW620, derived from different stages of colon carcinoma in the same patient, have been used for a number of biochemical, immunological, and genetic studies on colon cancer. A comparative analysis of their karyotypes may identify chromosomal aberrations that might represent markers for metastatic spread. In the present study spectral karyotyping (SKY) was applied to these two colon cancer cell lines. Compared to previously reported G-banded karyotypes, 9 (SW480) and 7 (SW620) markers were identical, 3 (SW480) and 3 (SW620) markers could be redefined, 5 (SW480) and 8 (SW620) markers were newly identified, and 4 (SW480) and 5 (SW620) of the previous described markers could not be confirmed. The redefined aberrations include very complex rearrangements, such as a der(16) t(3;16;1;16;8;16; 1;16;10) and a der(18)t(18;15;17)(q12; p11p13;??) in SW620 and a der(19)t(19;8;19;5) in SW480, that have not been identified by conventional banding techniques. The resulting chromosome gains (5q11-->5q15, 7pter-->q22, 11, 13q14-->qter, 20pter-->p12, X) and losses (8pter-->p2, 18q12-->qter, Y) found in both SW480 and SW620 were in good agreement with those frequently described in colorectal tumors as primary changes in the stem cell. Abnormalities found exclusively in SW620 cells only (gains of 5pter-->5q11, 12q12-->q23, 15p13-->p11, and 16q21-->q24 and losses of 2pter-->2p24, 4q28-->qter, and 6q25-->qter) can be viewed as changes that occurred in a putative metastatic founder cell.
Asunto(s)
Neoplasias Abdominales/genética , Neoplasias Abdominales/secundario , Adenocarcinoma/genética , Adenocarcinoma/secundario , Aberraciones Cromosómicas/genética , Neoplasias del Colon/genética , Neoplasias Abdominales/patología , Adenocarcinoma/patología , Bandeo Cromosómico , Rotura Cromosómica/genética , Deleción Cromosómica , Neoplasias del Colon/patología , Amplificación de Genes/genética , Duplicación de Gen , Marcadores Genéticos/genética , Humanos , Cariotipificación , Masculino , Estadificación de Neoplasias , Oncogenes/genética , Proteínas Tirosina Quinasas Receptoras/genética , Translocación Genética/genética , Células Tumorales CultivadasRESUMEN
The German Thorotrast study comprises 2,326 patients and 1,890 controls. Forty-eight Thorotrast patients and 239 controls are still alive and are invited for a follow-up examination every 2 years. In the deceased patients, the following neoplastic diseases with excess rates were registered (Thorotrast/controls): liver cancer (454/3); cancer of the bile ducts, including gallbladder (42/7); myeloid leukemia (40/7); myelodysplastic syndrome (30/4); plasmacytoma (10/2); non-Hodgkin's lymphoma (15/5); bone sarcoma (4/1); malignant peritoneal or pleural mesothelioma (9/0). Dose calculations are based on results of whole-body counting, X-ray films, and data obtained from the hospital records on the volume of Thorotrast injected. For liver cancer, the cumulative risk estimate was calculated to be 40 per 10(4) person Sv (radiation weighting factor = 20). These figures are close to the results of the Danish study and are comparable to the results of the Life Span Study of A-bomb survivors after 40 years at risk with 18 to 48 liver cancers per 10(4) person Sv. For hematopoietic malignancies, the cumulative risk was calculated to be about 7 per 10(4) person Sv (radiation weighting factor = 20). This risk estimate is lower by a factor of 10 compared to the results of the Life Span Study.
Asunto(s)
Neoplasias Inducidas por Radiación/etiología , Medición de Riesgo , Dióxido de Torio/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Leucemia Inducida por Radiación/etiología , Neoplasias Hepáticas/etiología , Persona de Mediana Edad , Dosis de RadiaciónRESUMEN
AIMS: The X-ray contrast medium Thorotrast, used worldwide between 1930 to 1950 predominantly for arteriography, consisted of a colloidal solution of thorium dioxide. The radioactive thorium-232 (half-life 1.4x10(10) years) is stored lifelong in the organs of the reticulo-endothelial system after intravascular injection, causing chronic exposure to alpha radiation. The aim of the German Thorotrast study is the assessment of radiation late effects and the calculation of risk estimates. MATERIAL AND METHODS: The German Thorotrast study started in 1968 as a cohort study and comprises 2326 Thorotrast patients and 1890 patients of a matched control group. The Thorotrast patients who were still alive at the beginning of the study were examined by X-ray plain films of the upper abdomen and of the injection site of the contrast medium as well as by whole-body counter measurements. At the beginning we offered the patients ultrasound and later on CT and MRI at regular intervals for early detection of liver cancer. RESULTS: To date 454 primary liver cancers have been registered in the group of Thorotrast patients compared to 3 cases in the control group. With the help of modern imaging methods relatively small liver cancers were detected and could be surgically removed. DISCUSSION: There is a correlation between the mean accumulated dose to the liver and the incidence of liver cancer. The cumulative risk for liver malignancies is about 600 diseases per 10(4) persons whose liver was exposed to 1 Gy. Also the incidence of liver cirrhosis is correlated with the mean accumulated dose to the liver.